Search results: Sage Journals

Restricted accessCase reportFirst published December, 2022

Embolia Cutis Medicamentosa (Nicolau Syndrome) Secondary to Intramuscular Fulvestrant Injection: A Case Report

Joshua L. Murdock, Marissa R. Duco, Subhash C. Sharma [...]

Journal of Pharmacy Practice

Restricted accessResearch articleFirst published September, 2006

Fulvestrant: Pharmacologic Profile Versus Existing Endocrine Agents for the Treatment of Breast Cancer

Aman U Buzdar, John FR Robertson

Annals of Pharmacotherapy

Open accessReview articleFirst published July, 2017

Fulvestrant in advanced breast cancer: evidence to date and place in therapy

Katalin Boér

Therapeutic Advances in Medical Oncology

Restricted accessAnnouncementFirst published July, 2016

Body Mass Index and Clinical Benefit of Fulvestrant in Postmenopausal Women with Advanced Breast Cancer

Arpine Gevorgyan, Giacomo Bregni, Giulia Galli [...]

Tumori Journal

Open accessResearch articleFirst published 2023

Quality of life with palbociclib plus fulvestrant versus placebo plus fulvestrant in postmenopausal women with endocrine-sensitive hormone receptor-positive and HER2-negative advanced breast cancer: patient-reported outcomes from the FLIPPER trial

Ariadna Tibau, M. Teresa Martínez, Manuel Ramos [...]

Therapeutic Advances in Medical Oncology

Restricted accessResearch articleFirst published December, 2012

Cost-effectiveness of fulvestrant 250 mg versus 500 mg in postmenopausal women with estrogen receptor-positive metastatic breast cancer and disease progression after antiestrogen therapy

Matthew J Newman, Laura T Jones, Jacqueline M Kraft [...]

Journal of Oncology Pharmacy Practice

Restricted accessResearch articleFirst published 2026

Mining of Respiratory System Toxicity Risk Signals for Fulvestrant Based on the Tianjin Adverse Reaction Monitoring Center and the FDA Adverse Event Reporting System Database

Meisa Wang, Qiushuang Han, Yuan Jiang [...]

Hospital Pharmacy

Open accessReview articleFirst published 2025

Capivasertib/Fulvestrant in patients with HR+,HER2-low or HER2-negative locally advanced or metastatic breast cancer

Karam Aboud, Magda Meissner, Rob Jones

Therapeutic Advances in Medical Oncology

Open accessResearch articleFirst published 2019

Patterns of treatment and outcome with 500-mg fulvestrant in postmenopausal women with hormone receptor-positive/HER2-negative metastatic breast cancer: a real-life multicenter Italian experience

Raffaella Palumbo, Federico Sottotetti, Erica Quaquarini [...]

Therapeutic Advances in Medical Oncology

Restricted accessOtherFirst published December, 2002

Fulvestrant;Oxaliplatin

Dominic A. Solimando, J. Aubrey Waddell

Hospital Pharmacy

Restricted accessCase reportFirst published December, 2022

Embolia Cutis Medicamentosa (Nicolau Syndrome) Secondary to Intramuscular Fulvestrant Injection: A Case Report

Joshua L. Murdock, Marissa R. Duco, Subhash C. Sharma [...]

Journal of Pharmacy Practice

Restricted accessResearch articleFirst published September, 2006

Fulvestrant: Pharmacologic Profile Versus Existing Endocrine Agents for the Treatment of Breast Cancer

Aman U Buzdar, John FR Robertson

Annals of Pharmacotherapy

Open accessReview articleFirst published July, 2017

Fulvestrant in advanced breast cancer: evidence to date and place in therapy

Katalin Boér

Therapeutic Advances in Medical Oncology

Restricted accessAnnouncementFirst published July, 2016

Body Mass Index and Clinical Benefit of Fulvestrant in Postmenopausal Women with Advanced Breast Cancer

Arpine Gevorgyan, Giacomo Bregni, Giulia Galli [...]

Tumori Journal

Open accessResearch articleFirst published 2023

Quality of life with palbociclib plus fulvestrant versus placebo plus fulvestrant in postmenopausal women with endocrine-sensitive hormone receptor-positive and HER2-negative advanced breast cancer: patient-reported outcomes from the FLIPPER trial

Ariadna Tibau, M. Teresa Martínez, Manuel Ramos [...]

Therapeutic Advances in Medical Oncology

Restricted accessResearch articleFirst published December, 2012

Cost-effectiveness of fulvestrant 250 mg versus 500 mg in postmenopausal women with estrogen receptor-positive metastatic breast cancer and disease progression after antiestrogen therapy

Matthew J Newman, Laura T Jones, Jacqueline M Kraft [...]

Journal of Oncology Pharmacy Practice

Restricted accessResearch articleFirst published 2026

Mining of Respiratory System Toxicity Risk Signals for Fulvestrant Based on the Tianjin Adverse Reaction Monitoring Center and the FDA Adverse Event Reporting System Database

Meisa Wang, Qiushuang Han, Yuan Jiang [...]

Hospital Pharmacy

Open accessReview articleFirst published 2025

Capivasertib/Fulvestrant in patients with HR+,HER2-low or HER2-negative locally advanced or metastatic breast cancer

Karam Aboud, Magda Meissner, Rob Jones

Therapeutic Advances in Medical Oncology

Open accessResearch articleFirst published 2019

Patterns of treatment and outcome with 500-mg fulvestrant in postmenopausal women with hormone receptor-positive/HER2-negative metastatic breast cancer: a real-life multicenter Italian experience

Raffaella Palumbo, Federico Sottotetti, Erica Quaquarini [...]

Therapeutic Advances in Medical Oncology

Restricted accessOtherFirst published December, 2002

Fulvestrant;Oxaliplatin

Dominic A. Solimando, J. Aubrey Waddell

Hospital Pharmacy